Time and location of specialty palliative care for women dying with metastatic breast cancer
- PMID: 40663313
- DOI: 10.1007/s10549-025-07780-w
Time and location of specialty palliative care for women dying with metastatic breast cancer
Abstract
Background: Despite guideline recommendations, evidence suggests many women with metastatic breast cancer (mBC) do not receive specialty palliative care services despite high morbidity burden. Given the varied prognoses and disease trajectories of women with mBC, relatively little is known about palliative care delivery in this growing population, including timing and frequency of visits, location (inpatient vs. outpatient), and reasons for referral.
Methods: Using electronic health record and tumor registry data from a North Texas Comprehensive Cancer Center (2010-2023), we identified women who died with de novo or recurrent mBC. We examined receipt of palliative care (inpatient and outpatient), reasons for referral, and timing of palliative care encounters by duration of patient survival. We used multivariable logistic regression to assess associations between receipt of specialty palliative care and demographic, clinical, and survival characteristics.
Results: Among 265 women with mBC, 55.5% received no palliative care. Only women with short survival (< 18 months) received palliative care within 8 weeks of diagnosis. Most palliative care encounters were inpatient and occurred within ~ 1 month of death. In adjusted models, comorbidities and younger age were strongly associated with receiving outpatient palliative care. Most women were referred to palliative care for multiple reasons, with long-term survivors more likely to be referred for goals of care discussions alone.
Conclusion: Palliative care for women with mBC is infrequent and often late, with referrals seemingly driven by the imminence of death rather than metastatic diagnosis. Strategies to better identify and triage specialty palliative care needs and make timely referrals are needed.
Keywords: End-of-life; Metastatic; Palliative care; Supportive care.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Oncologic outpatient specialty palliative care referral uptake: a single institution quality improvement project.Ann Palliat Med. 2025 Jul;14(4):332-344. doi: 10.21037/apm-25-39. Ann Palliat Med. 2025. PMID: 40769729
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
References
-
- Caswell-Jin JL, Plevritis SK, Tian L et al (2018) Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr 2:pky062. https://doi.org/10.1093/jncics/pky062 - DOI - PubMed - PMC
-
- Gogate A, Wheeler SB, Reeder-Hayes KE et al (2021) Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. JNCI Cancer Spectr 5:pkab063. https://doi.org/10.1093/jncics/pkab063 - DOI - PubMed - PMC
-
- Cardoso F, Spence D, Mertz S et al (2018) Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast Edinb Scotl 39:131–138. https://doi.org/10.1016/j.breast.2018.03.002 - DOI
-
- Williamson TJ, Love SM, Clague DeHart JN et al (2018) Metastatic breast cancer collateral damage project (MBCCD): scale development and preliminary results of the survey of health, impact, needs, and experiences (SHINE). Breast Cancer Res Treat 171:75–84. https://doi.org/10.1007/s10549-018-4823-x - DOI - PubMed - PMC
-
- Lewis S, Yee J, Kilbreath S, Willis K (2015) A qualitative study of women’s experiences of healthcare, treatment and support for metastatic breast cancer. Breast Edinb Scotl 24:242–247. https://doi.org/10.1016/j.breast.2015.02.025 - DOI
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical